Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.63 |
| ▸ | NR4A2 | P43354 | 4/20 | 0.62 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.56 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.54 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | HPD | P32754 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | GUSB | P08236 | 1/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.50 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8354367 | 0.87 | MAOB (0.66) | MAOBNR4A2SMPD1SRD5A2PTPN1 | |
| SCHEMBL17978704 | 0.87 | MAOB (0.66) | MAOBNR4A2SMPD1SRD5A2PTPN1 | |
| SCHEMBL22749297 | 0.84 | AKR1C3 (0.55) | ALDH1A1MEN1KMT2A | |
| SCHEMBL340106 | 0.84 | MAOB (0.69) | MAOBNR4A2SMPD1SRD5A2PTPN1 | |
| SCHEMBL70333 | 0.82 | PTPN1 (0.73) | MAOBNR4A2SMPD1SRD5A2PTPN1 | |
| SCHEMBL12596970 | 0.81 | MAOB (0.59) | MAOBNR4A2SMPD1SRD5A2PTPN1 | |
| SCHEMBL9006943 | 0.81 | CES2 (0.56) | MAOBALDH1A1MEN1KMT2A | |
| SCHEMBL1765505 | 0.81 | MAOB (0.57) | MAOBNR4A2SMPD1SRD5A2PTPN1 | |
| SCHEMBL11270791 | 0.80 | ALDH1A1 (0.57) | ALDH1A1MEN1KMT2A | |
| SCHEMBL1819500 | 0.80 | PTPN1 (0.68) | MAOBNR4A2SMPD1SRD5A2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365085-B2 | Compounds and methods | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-29 | — | — | US | disclosed |
| EP-1575495-A2 | COMPOUNDS AND METHODS | SmithKline Beecham Corporation (US) | 2005-09-21 | — | — | EP | disclosed |
| US-20050113580-A1 | Amide compounds and methods of using the same | SMITHKLINE BEECHAM CORP | 2005-05-26 | — | — | US | disclosed |
| WO-2003082205-A2 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113580-A1 | Amide compounds and methods of using the same | NR1H2, NR1H3, PPARA | MAOB 3322/4885NR4A2 102/4885SMPD1 464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.